IMUNON, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.17 USD | +4.00% |
|
-26.42% | +72.06% |
| Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
| Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.52
x | P/E ratio 2025 * |
-0.68
x | Employees | 33 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Imunon, Inc.
More press releases
| 1 day | +4.00% | ||
| 1 week | -26.42% | ||
| Current month | -28.66% | ||
| 1 month | +45.16% | ||
| 3 months | +105.26% | ||
| 6 months | +18.11% | ||
| Current year | +72.06% |
1 week
1.04
1.60
1 month
0.782.00
Current year
0.482.00
1 year
0.482.00
3 years
0.4823.25
5 years
0.4897.50
10 years
0.48783.31
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Tardugno
CHM | Chairman | 73 | 07-01-02 |
Jeffrey Church
DFI | Director of Finance/CFO | 67 | 10-07-05 |
Sebastien Hazard
CTO | Chief Tech/Sci/R&D Officer | 53 | Dec. 10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 21-06-07 | |
Frederick Fritz
BRD | Director/Board Member | 73 | 11-07-07 |
James Dentzer
BRD | Director/Board Member | 57 | 22-10-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.17 | +4.00% | 95,137 |
| 24-04-18 | 1.125 | -1.32% | 204,868 |
| 24-04-17 | 1.14 | -16.79% | 149,608 |
| 24-04-16 | 1.37 | -6.80% | 94,992 |
| 24-04-15 | 1.47 | -7.55% | 126,431 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.17
USD
Average target price
12
USD
Spread / Average Target
+925.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +72.06% | 11M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
- Stock Market
- Equities
- IMNN Stock
